Denali Therapeutics Inc (DNLI)

09:58 AM

(DNLI) On The My Stocks Page - news.stocktradersdaily.com

09:58 AM

May 28, 2025

Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail

May 28, 2025

May 27, 2025

Stifel maintains Buy on Denali Therapeutics stock, $37 target - Investing.com

May 27, 2025

May 27, 2025

Stifel maintains Buy on Denali Therapeutics stock, $37 target By Investing.com - Investing.com UK

May 27, 2025

May 26, 2025

Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com

May 26, 2025

May 21, 2025

When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com

May 21, 2025

May 20, 2025

Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 20, 2025

May 20, 2025

Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com

May 20, 2025

May 19, 2025

Denali Therapeutics (DNLI) Receives a Price Target Adjustment fr - GuruFocus

May 19, 2025

May 19, 2025

Denali Therapeutics (DNLI) Receives a Price Target Adjustment from B of A Securities | DNLI Stock News - GuruFocus

May 19, 2025

May 19, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by Analyst | DN - GuruFocus

May 19, 2025

May 13, 2025

Denali Therapeutics shares fall after price target cut to $32 By Investing.com - Investing.com Nigeria

May 13, 2025

May 11, 2025

Where are the Opportunities in (DNLI) - news.stocktradersdaily.com

May 11, 2025

May 08, 2025

Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - MSN

May 08, 2025

May 08, 2025

Hunter Syndrome Treatment Market Expands with Enzyme - openPR.com

May 08, 2025

May 08, 2025

Denali Therapeutics (DNLI) Price Target Reduced to $30 by Analys - GuruFocus

May 08, 2025

May 08, 2025

Denali Therapeutics shares fall after price target cut to $32 - Investing.com

May 08, 2025

May 08, 2025

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance

May 08, 2025

May 08, 2025

Denali Therapeutics (DNLI) Price Target Revised Amid Strategic D - GuruFocus

May 08, 2025

May 08, 2025

Denali Therapeutics Advances Pipeline Amid Financial Loss - TipRanks

May 08, 2025

May 07, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwrigh - GuruFocus

May 07, 2025

May 07, 2025

Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwright & Co. | DNLI Stock News - GuruFocus

May 07, 2025

May 07, 2025

Denali Therapeutics (DNLI) Price Target Revised Amid Strategic Developments | DNLI Stock News - GuruFocus

May 07, 2025

May 07, 2025

Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright - TipRanks

May 07, 2025

May 07, 2025

Decoding Denali Therapeutics Inc (DNLI): A Strategic SWOT Insigh - GuruFocus

May 07, 2025

May 06, 2025

Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 06, 2025

May 06, 2025

Denali Therapeutics Reports First Quarter 2025 Financial - GlobeNewswire

May 06, 2025

May 06, 2025

Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care - Stock Titan

May 06, 2025

May 05, 2025

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView

May 05, 2025

May 01, 2025

Biogen (BIIB) Completes Enrollment for Parkinson's Treatment Stu - GuruFocus

May 01, 2025

Apr 22, 2025

First Week of December 19th Options Trading For Denali Therapeutics (DNLI) - Nasdaq

Apr 22, 2025

Apr 15, 2025

(DNLI) Technical Data - news.stocktradersdaily.com

Apr 15, 2025

Apr 10, 2025

Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com

Apr 10, 2025

Apr 10, 2025

Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials, and Key Companies Involved by DelveInsight | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma - The Globe and Mail

Apr 10, 2025

Apr 07, 2025

Denali Announces Rolling Regulatory Submission of Tividenofusp Alfa for Hunter Syndrome - Neurology live

Apr 07, 2025

Apr 05, 2025

Denali Therapeutics stock hits 52-week low at $12.05 - Investing.com Australia

Apr 05, 2025

Apr 05, 2025

Denali Therapeutics stock hits 52-week low at $12.05 By Investing.com - Investing.com Canada

Apr 05, 2025

Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025

Apr 03, 2025

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Zacks Investment Research

Apr 03, 2025

Apr 02, 2025

Denali Therapeutics set to advance groundbreaking treatments for neurological diseases - MSN

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics advances Hunter syndrome treatment BLA By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

What Happened To Denali Therapeutics Stock Wednesday? - Benzinga

Apr 02, 2025

Apr 02, 2025

Sector Update: Health Care Stocks Advance in Late Afternoon Trading - TradingView

Apr 02, 2025

Apr 02, 2025

Sector Update: Health Care - MarketScreener

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics begins marketing application for genetic disorder drug, shares rise - TradingView

Apr 02, 2025

Apr 02, 2025

Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier - BioSpace

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up - MarketScreener

Apr 02, 2025

Apr 02, 2025

How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics Announces Initiation of BLA Filing for - GlobeNewswire

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics advances Hunter syndrome treatment BLA - Investing.com

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome - MarketScreener

Apr 02, 2025